Abstract
CS-905, (±)-3-(1 -diphenylmethylazetidin-3-yl)5-isopropyl 2-amino-1, 4-dihydro-6-methyl-4-(m-nitrophenyl)-3, 5-pyridine-dicarboxylate, is a novel dihydropyridine calcium blocker. Both CS-905 and nicardipine, when administered orally, produced a dose-dependent fall of blood pressure in conscious perinephritic hypertensive dogs. Unlike the hypotensive effect of nicardipine, that of CS-905 has a gradual onset and is long-lasting, with little increase in the heart rate and plasma renin activity (PRA). The lack of both tachycardia and increase of PRA is probably mostly due to the slow onset of antihypertensive action following CS-905.
